Skip to main content

Advertisement

Fig. 4 | Cell & Bioscience

Fig. 4

From: Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease

Fig. 4

pNGVL4a-CRT-E6E7L2 or pNGVL4a-CRT/E7(detox) DNA prime followed by TA-CIN boost also generated significantly enhanced HPV16 E7-specific CD8+ T cell responses. Five to eight weeks old female C57BL/6 mice (5 mice/group) were vaccinated with either 5 μg/mouse of pNGVL4a-CRT/E7(detox) DNA or pNGVL4a-CRT-E6E7L2 in 50 μl via intramuscular injection (leg muscle) or 25 μg/mouse of TA-CIN in 20 μl via i.d. injection. The mice were boosted as indicated twice with 1-week interval. Seven days after last vaccination, PBMCs were prepared and stained with anti-mouse CD8 and HPV16 E7 tetramer. PBMCs were prepared and stained with anti-mouse CD8 and HPV16 E7 tetramer. The data were acquired with FACSCalibur and analyzed with CellQuest. a Schematic illustration of the experiment. b and c Flow cytometry analysis of HPV16 E7-specific CD8+ T cells in peripheral blood induced by pNGVL4a-CRT/E7(detox) DNA and TA-CIN vaccination. d and e Flow cytometry analysis of HPV16 E7-specific CD8+ T cells in peripheral blood induced by pNGVL4a-CRT-E6E7L2 DNA and TA-CIN vaccination

Back to article page